Skip To Content

This site is for U.S. healthcare professionals only

Prescribing InformationPatient Site

Starting and staying on treatment

Treating your patients with MYQORZO™

Pill bottle with arrows representing titration

Flexibility to rapidly titrate as early as 2 weeks¹*

Dose may be titrated after each echocardiogram¹
Echocardiogram within 2 to 8 weeks, adaptable to the needs of your patient¹
No monthly drug-to-drug interaction screenings required for your patients with the pharmacy

Monitor every 6 months¹

Echocardiogram every 6 months for patients with LVEF ≥55%¹
- Every 3 months if LVEF is <55% and ≥50%¹
No monthly drug-to-drug interaction screenings required for your patients with the pharmacy

*Echocardiogram performed within 2 to 8 weeks after treatment initiation or dose adjustment. Dose adjustment based on assessed LVEF and LVOT gradient or drug interaction. After a treatment interruption due to low LVEF, resume treatment no earlier than 7 days, when LVEF ≥55% and re-initiate dose titration at the starting dose of 5 mg.¹

REMS program overview

MYQORZO is only available through the MYQORZO Risk Evaluation and Mitigation Strategy (REMS) Program to mitigate the risk of heart failure due to systolic dysfunction.¹

REMS enrollment will be available soon

A one-time REMS certification and patient enrollment are required

A one-time REMS certification and patient enrollment are required

Echocardiogram and Patient Monitoring Form schedule¹

Before initiating MYQORZO

Icons of a patient, an echocardiogram, and a REMS Patient enrollment Form

Submit a REMS Patient
Enrollment Form

Recommended
starting dose

5 mg
once
daily

2 to 8 weeks
after initiating treatment

Icons of pill bottle, echocardiogram, and Patient Monitoring Form

Submit a Patient
Monitoring Form

2 to 8 weeks
after each dose change

Icons of pill bottle, echocardiogram, and Patient Monitoring Form

Submit a Patient
Monitoring Form

Every 6 months
while in maintenance^†

Submit a Patient
Monitoring Form

Before initiating MYQORZO

Submit a REMS Patient
Enrollment Form

Icons of a patient, an echocardiogram, and a REMS Patient enrollment Form

Recommended starting dose:

5 mg
once
daily

2 to 8 weeks after
initiating treatment

Submit a Patient
Monitoring Form

Icons of pill bottle, echocardiogram, and Patient Monitoring Form

2 to 8 weeks after
each dose change

Submit a Patient
Monitoring Form

Icons of pill bottle, echocardiogram, and Patient Monitoring Form

Every 6 months while
in maintenance^†

Submit a Patient
Monitoring Form

^†After the maintenance dose has been established, assess LVEF and Valsalva LVOT gradient every 6 months, or every 3 months in patients with LVEF <55% to ≥50%. Consider monitoring LVEF and adjust the dose per the dosing table as needed, in patients with an intercurrent illness (eg, severe infection or COVID-19), new arrhythmia (eg, new or uncontrolled atrial fibrillation or other uncontrolled tachyarrhythmia) or any other conditions that may impair systolic function. Do not increase the dose until the intercurrent illness or new arrhythmia has resolved or stabilized.¹

Reach out to a MYQORZO Navigator if you have any questions about REMS

at 844-285-7367, Monday through Friday, 8 AM to 8 PM ET.

at 844-285-7367, Monday through Friday, 8 AM to 8 PM ET.

Learn more about dosing and titration with MYQORZO

Review dosing information

Find out about personalized patient support

Discover the Patient Support Program

COVID-19=coronavirus disease 2019; LVEF=left ventricular ejection fraction; LVOT=left ventricular outflow tract.

Reference: 1. MYQORZO (aficamten). Prescribing information. Cytokinetics; 2025.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE

MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.

Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction.

Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program.

CONTRAINDICATIONS

MYQORZO is contraindicated with concomitant use of rifampin.

WARNING AND PRECAUTIONS

Heart Failure
MYQORZO reduces cardiac contractility, which can reduce LVEF and cause heart failure.

Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, new or uncontrolled atrial fibrillation) may be at greater risk of developing systolic dysfunction and heart failure.

Assess patients’ clinical status and LVEF prior to and during treatment and adjust the MYQORZO dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide may be signs and symptoms of heart failure.

Initiation of MYQORZO in patients with LVEF <55% is not recommended.

MYQORZO REMS Program

MYQORZO is available only through a restricted program called the MYQORZO REMS Program, because of the risk of heart failure due to systolic dysfunction.

Notable requirements of the MYQORZO REMS Program include:

Prescribers must be certified by enrolling in the MYQORZO REMS Program
Patients must enroll in the MYQORZO REMS Program and comply with ongoing monitoring requirements
Pharmacies must be certified by enrolling in the MYQORZO REMS Program and must only dispense to patients who are authorized to receive MYQORZO
Wholesalers and distributors must only distribute to certified pharmacies

Further information is available at www.MYQORZOREMS.com, or at 1-844-285-7367.

Cytochrome P450 Interactions Leading to Heart Failure or Loss of Effectiveness
MYQORZO is metabolized primarily by CYP2C9, and to a lesser extent by CYP3A, CYP2D6, and CYP2C19 enzymes. Initiation of medications that inhibit multiple P450 pathways of MYQORZO elimination (eg, fluconazole, voriconazole, or fluvoxamine) or strong CYP2C9 inhibitors, and discontinuation of moderate-to-strong CYP3A inducers may lead to increased blood concentrations of aficamten and increase the risk of heart failure due to systolic dysfunction. Conversely, initiation of medications that induce P450 pathways of MYQORZO (eg, rifampin, moderate-to-strong CYP3A inducers) may lead to decreased blood concentrations of aficamten and potential loss of effectiveness. Assess LVEF 2 to 8 weeks after initiation of such inhibitors or after discontinuation of such inducers and adjust the dose of MYQORZO accordingly.

Advise patients of the potential for drug interactions. Advise patients to inform their healthcare provider of all concomitant medications prior to and during MYQORZO treatment.

ADVERSE REACTIONS

Hypertension (8% vs 2%) was the only adverse reaction occurring in >5% of patients and more commonly on MYQORZO than on placebo in the pivotal trial.

INDICATIONS AND USAGE

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

Please see full Prescribing Information, including Boxed WARNING.